Pain Flashcards

(31 cards)

1
Q

chronic non-cancer pain (CNCP) definition

A

musculoskeletal pain
caused by lesion or disease of the ms system (muscles, ligaments, tendons, joints)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

consequences to failure to use multimodal approach

A

miss the benefits of physical, behavioral, and psychological approaches to train the nervous system and maximize recovery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

consequences to failure to target the mechanism of pain

A

suboptimal pain control and increased costs when pain control is not effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

consequences to failure to treat neuropathic pain with adjuvant medications

A

worsening hypersensitivity of nervous system and suboptimal pain control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

consequences to heavy use of short acting opioids instead of long acting opioids

A

increased breakthrough pain, disturbed sleep, development of opioid tolerance, APAP toxicity with combo products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

pain assessment

A

PQRST, pain scales, FLACC scale
P: palliative/provocative
Q: quality
R: radiation
S: severity
T: temporal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

barriers to recognition of pain

A

no objective markers of pain, blunted response, cognitive & communication, co-morbidities, staff training

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

common misconceptions about chronic pain

A

sign of personal weakness, part of aging, punishment, death is near, indicates serious illness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

nonspecific s/s of pain

A

frowning, grimacing, clenched teeth, bracing, guarding, restlessness, agitation, eating/sleeping poorly, sighing, groaning, loss of function, change in gait/behavior, decreased activity levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

factors associated with the development of chronic pain in elderly

A

degenerative joint disease, RA, osteoporosis, neuropathic pain, HA, oral/dental pathology, PVD, amputations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

non-pharm pain management

A

physical activity, patient education, cognitive-behavioral therapies, adjuncts (heat/cold, massages, spirituality)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

steps in treating pain

A
  1. nonopioid +/- adjuvant
  2. opioid for mild-to-mod pain +/- adjuvant, +/- nonopioid
  3. opioid for mod-to-severe pain +/- nonopioid, +/- adjuvant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

general principles for prescribing pain control in long-term care settings

A

● admin meds routinely, not prn
● use least invasive route of admin first
● begin with low dose, titrate carefully
● reassess and adjust dose frequently

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

non-opioid analgesic- acetaminophen pro

A

useful for mild-to-mod pain, elder safe, adjunctive, starting point

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

non-opioid analgesic- acetaminophen con

A

very few: caution in hepatic failure, watch total use (<4gm/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

non-opioid analgesic- NSAID pro

A

useful for mild-to-mod pain, musculoskeletal (inflammation, cancer), topical diclofenac
may be selected carefully in safer therapies have failed

17
Q

non-opioid analgesic- NSAID con

A

“ceiling effect”, toxicity, absolute CIs (PUD, CKD, HF)

18
Q

bottom line with NSAIDs in elders

A

evaluate for risk vs. benefit, use lowest possible effective dose, analgesic vs. anti-inflammatory, COX-2 may be safer, GI prophylaxis for patients at risk

19
Q

Journavx (suzetrigine) 50 mg tabs

A

approved for short term (14 day) use for acute moderate and severe pain (non-opioid)

20
Q

adjunctive agents

A

duloxetine (chronic musculoskeletal pain), lidocaine
avoid TCAs

21
Q

neuropathic pain treatment

A

first line: a-2 ligands (pregabalin, gabapentin), SNRIs, TCAs (CAUTION)
second line: topical agents (lidocaine, capsaicin)

22
Q

opioid analgesic pro

A

mod-to-severe pain, ceiling dose, routes of admin, long acting agents available
all patients with mod-to-severe pain should be CONSIDERED for opioid treatment

23
Q

opioid analgesic in elders side effects vs toxicity- pulmonary

A

respiratory depression vs. severe resp. depression and apnea

24
Q

opioid analgesic in elders side effects vs toxicity- CNS

A

lethargy vs. ↓ LOC, unarousable

25
opioid analgesic in elders side effects vs toxicity- ocular
miosis vs. fixed, pinpoint pupils
26
preferred analgesics in elders
morphine, hydrocodone, oxycodone, hydromorphone, fentanyl
27
opioid conversions
28
specific risks of transdermal formulations
active ingredient may still be present after therapeutic obsolescence, improper disposal could lead to unintended exposure, external heat could impact rate of absorption and AEs, products with metal foil backing preclude use if MRI is necessary
29
management of opioid induced GI effects- N/V
haloperidol, antihistamines, anticholinergics, ondansetron, metoclopramide, lorazepam
30
management of opioid induced GI effects- constipation
softeners (docusate), stimulants (bisacodyl, Senna), osmotics (glycerin, lactulose, PEG), saline (mag citrate), opioid antagonists (naloxone, naloxegol), lubricant (mineral oil)
31
guidelines for prescribing opioids for pain is not applicable to:
sickle cell disease, cancer pain, palliative care or end of life care